H-group (homology)
304.31 HMG-CoA reductase
Ligands and drugs
663
Member domains
315
with ligand contacts (≤ 4 Å)
47.5% of members
282
with DrugDomain annotations
42.5% of members
215
with a DrugBank compound
32.4% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 304.31 belongs to X-group 304 Alpha-beta plaits, which binds 8.8 ligand superclasses per 20 proteins, broader than 75% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB16833 | ADP | Adenosine disphosphate | 33 |
| DB03461 | NAP | Nicotinamide adenine dinucleotide phosphate | 28 |
| DB03169 | HMG | (S)-Hmg-Coa | 21 |
| DB04377 | MAH | Meglutol | 15 |
| DB03518 | MEV | Mevalonic acid | 14 |
| DB14128 | NAD | Nadide | 14 |
| DB01992 | COA | Coenzyme A | 11 |
| DB00439 | 116 | Cerivastatin | 8 |
| DB01076 | 117 | Atorvastatin | 8 |
| DB01095 | 115 | Fluvastatin | 8 |
| DB01098 | FBI | Rosuvastatin | 8 |
| DB04447 | DTT | 1,4-Dithiothreitol | 7 |
| DB14714 | SIM | Tenivastatin | 6 |
| DB02338 | NDP | NADPH | 3 |
| DB08860 | — | Pitavastatin | 3 |
| DB00157 | — | NADH | 2 |
| DB00175 | — | — | 2 |
| DB00227 | — | Lovastatin | 2 |
| DB00641 | — | — | 2 |
| DB03785 | LVA | Mevinolinic acid | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ADP | ADENOSINE-5'-DIPHOSPHATE | 34 |
| NAP | NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE | 28 |
| NAD | NICOTINAMIDE-ADENINE-DINUCLEOTIDE | 26 |
| MEV | (R)-MEVALONATE | 24 |
| HMG | 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A | 21 |
| COA | COENZYME A | 19 |
| CAmetal | CALCIUM ION | 17 |
| 882 | (3R,5R)-7-[5-(ANILINOCARBONYL)-3,4-BIS(4-FLUOROPHENYL)-1-ISOPROPYL-1H-PYRROL-2-YL]-3,5-DIHYDROXYHEPTANOIC ACID | 16 |
| MAH | 3-HYDROXY-3-METHYL-GLUTARIC ACID | 16 |
| 117 | 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID | 10 |
| 114 | (3R,5R)-3,5-dihydroxy-7-[(1S,2S,8S,8aR)-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid | 8 |
| 115 | (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | 8 |
| 116 | 7-[4-(4-FLUORO-PHENYL)-5-HYDROXYMETHYL-2,6-DIISOPROPYL-PYRIDIN-3-YL]-3,5-DIHYDROXY-HEPTANOIC ACID | 8 |
| 3HI | (3R,5R)-7-[2-(4-fluorophenyl)-4-[(2-hydroxyphenyl)carbamoyl]-5-(1-methylethyl)-3-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid | 8 |
| 4HI | (3R,5R)-7-[4-(benzylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-1H-imidazol-1-yl]-3,5-dihydroxyheptanoic acid | 8 |
| 5HI | (3R,5R)-7-[2-(4-fluorophenyl)-4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}-5-(1-methylethyl)-1H-imidazol-1-yl]-3,5-dihydroxyheptanoic acid | 8 |
| 6HI | (3R,5R)-7-{2-[(4-fluorobenzyl)carbamoyl]-4-(4-fluorophenyl)-1-(1-methylethyl)-1H-imidazol-5-yl}-3,5-dihydroxyheptanoic acid | 8 |
| 7HI | (3R,5R)-7-[3-(biphenyl-4-ylcarbamoyl)-2-ethyl-5,6,7,8-tetrahydrocyclohepta[b]pyrrol-1(4H)-yl]-3,5-dihydroxyheptanoic acid | 8 |
| 8HI | (3R,5R)-7-{3-(4-fluorophenyl)-1-(1-methylethyl)-4-phenyl-5-[(4-sulfamoylphenyl)carbamoyl]-1H-pyrrol-2-yl}-3,5-dihydroxyheptanoic acid | 8 |
| 9HI | (3R,5R)-7-{3-[(4-carbamoylphenyl)sulfamoyl]-4,5-bis(4-fluorophenyl)-2-(1-methylethyl)-1H-pyrrol-1-yl}-3,5-dihydroxyheptanoic acid | 8 |